Atrial fibrilation. Persistent atrial fibrillation
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group are prescribed Ivabradine at a dose of 5 mg twice a day (manufactured by Kobel Daroo Company) for one month.24 hours ambulatory heart rhythm
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Non-paroxysmal atrial fibrillation at randomization, with no prospect of cardioversion, anti arrhythmic treatment with group I or III drugs, or pulmonary vein ablation Beta-blocker or nondihydropyridine calcium channel blocker or digoxin therapy at the maximum dose recommended for or tolerated by the patient Ventricular rate of more than 70 Be able to voluntarily give informed consent
Exclusion criteria
Exclusion criteria: Medical causes that explain poor heart rate control: fever, anemia, hyperthyroidism ,etc Patients with a known contraindication to Ivabradine Valve disease requiring surgical or percutaneous repair Impossibility to attend the visits scheduled in the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ventrical rate in non-paroxysmal atrial fibrillation patients. Timepoint: Before and one month after intervention. Method of measurement: 24 hours ambulatory heart rhythm monitoring. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean daytime ventricular rate. Timepoint: Before and one month after intervention. Method of measurement: 24 hours ambulatory heart rhythm monitoring.;Mean night time ventricular rate. Timepoint: Before and one month after intervention. Method of measurement: 24 hours ambulatory heart rhythm monitoring. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyede Houra Yeganegi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed